JonesTrading analyst Soumit Roy has maintained their bullish stance on AVBP stock, giving a Buy rating on August 12.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Soumit Roy has given his Buy rating due to a combination of factors that highlight ArriVent BioPharma, Inc.’s promising future prospects. The company is expected to release pivotal topline Phase 3 data for firmonertinib in the treatment of 1L EGFR ex20ins mutated NSCLC in early 2026, which is a significant milestone that could enhance its market position. Additionally, ArriVent plans to present final data from the EGFR PACC Phase 1b trial at the WCLC 2025, further solidifying its research advancements.
Another reason for the Buy rating is the company’s strong financial position, with approximately $335.6 million in cash and marketable securities, ensuring a solid cash runway. The valuation analysis, which includes DCF, NPV, and PE-based valuations, suggests a price target of $45, driven by potential peak sales and contributions from firmonertinib in different NSCLC mutations. These factors collectively indicate a positive outlook for ArriVent BioPharma, Inc., justifying the Buy recommendation.
In another report released on August 12, Citi also maintained a Buy rating on the stock with a $33.00 price target.